LITTLE KNOWN FACTS ABOUT PHARMACEUTICAL EXCIPIENTS.

In exactly the same 12 months the ITC also described on their attempts in the direction of the circulation syntheses of two lead compounds documented earlier by AstraZeneca. The primary a single details the flow synthesis of the strong 5HT1B antagonist (28) that was assembled by way of a five step continuous synthesis including a SNAr response, het